Gilead Sciences is a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines in areas of unmet medical need. The Company strives to transform and simplify care for people with life-threatening illnesses around the world. Gilead's portfolio of products and pipeline of investigational drugs includes treatments for HIV/AIDS, liver diseases, cancer, inflammatory and respiratory diseases, and cardiovascular conditions.
The Company's portfolio of marketed products includes a number of category firsts, including complete treatment regimens for HIV infection available in a once-daily single pill and the first oral antiretroviral pill available to reduce the risk of acquiring HIV infection in certain high-risk adults.

Type
Public
HQ
Foster City, US
Founded
1987
Size (employees)
9,000 (est)
Website
gilead.com
Gilead Sciences was founded in 1987 and is headquartered in Foster City, US
Report incorrect company information

Key People/Management at Gilead Sciences

John Milligan

John Milligan

CEO
Kevin Young

Kevin Young

COO

Gilead Sciences Office Locations

Gilead Sciences has offices in Foster City, Fremont, Oceanside, San Dimas and in 2 other locations
Foster City, US (HQ)
333 Lakeside Dr
Branford, US
36 E Industrial Rd
Fremont, US
7601 Dumbarton Cir
Oceanside, US
4049 Avenida De La Plata
San Dimas, US
650 Cliffside Dr
Seattle, US
199 E Blaine St
Show all (6)
Report incorrect company information

Gilead Sciences Financials and Metrics

Gilead Sciences Financials

Gilead Sciences's revenue was reported to be $26.11 b in FY, 2017
USD

Revenue (FY, 2017)

26.1 b

Gross profit (FY, 2017)

21.7 b

Gross profit margin (FY, 2017), %

83.3%

Net income (FY, 2017)

4.6 b

EBIT (FY, 2017)

14.1 b

Market capitalization (18-Apr-2018)

99.8 b

Cash (31-Dec-2017)

7.6 b

EV

123 b
Gilead Sciences's current market capitalization is $99.8 b.
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Revenue

11.2 b24.9 b32.6 b30.4 b26.1 b

Revenue growth, %

122%31%(7%)

Cost of goods sold

2.9 b3.8 b4 b4.3 b4.4 b

Gross profit

8.3 b21.1 b28.6 b26.1 b21.7 b
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017

Revenue

2.8 b5 b6.5 b6 b7.6 b8.2 b8.3 b7.8 b7.8 b7.5 b6.5 b7.1 b

Cost of goods sold

681.9 m813.2 m924.7 m987.3 m882 m998 m1.1 b1.2 b864 m1.1 b957 m1.1 b

Gross profit

2.1 b4.2 b5.6 b5.1 b6.7 b7.2 b7.2 b6.6 b6.9 b6.4 b5.5 b6 b

Gross profit Margin, %

75%84%86%84%88%88%87%85%89%85%85%84%
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Cash

2.1 b10 b12.9 b8.2 b7.6 b

Inventories

2.1 b1.4 b2 b1.6 b801 m

Current Assets

7.3 b17.7 b24.8 b20.4 b31.8 b

PP&E

1.2 b1.7 b2.3 b2.9 b3.3 b
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017

Cash

2 b6.4 b8.7 b6.2 b10.6 b7.4 b14 b6.3 b6.5 b9.8 b10.3 b8.7 b

Accounts Receivable

2 b3.2 b3.4 b2.9 b4.8 b5.3 b6.1 b

Inventories

1.9 b2.1 b2.1 b1.9 b1.9 b2 b2 b1.9 b1.9 b1.9 b1.5 b1.4 b

Current Assets

7 b13 b15.5 b12.6 b20.1 b18.1 b25.9 b19.3 b18.4 b21.4 b21.4 b28.6 b
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Net Income

3.1 b12.1 b18.1 b13.5 b4.6 b

Depreciation and Amortization

233 m

Inventories

(343.1 m)143 m(855 m)(488 m)(253 m)

Accounts Payable

(97.7 m)(289 m)226 m47 m(430 m)
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017

Net Income

785.2 m2.2 b3.7 b2.7 b4.3 b8.8 b13.4 b3.6 b7.1 b10.4 b2.7 b5.8 b

Depreciation and Amortization

75 m116 m42 m85 m129 m49 m103 m

Inventories

(634 m)(659 m)(14 m)(97 m)(274 m)(5 m)(14 m)

Accounts Payable

620 m288 m(239 m)(67 m)(115 m)(262 m)(399 m)
USDY, 2017

EV/EBIT

8.7 x

EV/CFO

10.3 x

EV/FCF

10.9 x

Revenue/Employee

2.9 m

Financial Leverage

3.4 x
Show all financial metrics

Gilead Sciences Operating Metrics

FY, 2016

Countries

30

Phase I Trials Products

3

Phase II Trials Products

12

Phase III Trials Products

6
Show all operating metrics

Gilead Sciences Acquisitions / Subsidiaries

Acquired CompanyDateDeal Size
Kite Pharma August 28, 2017$11.90 b
Report incorrect company information